Form 4: Fennec Pharmaceuticals CEO Rosty Raykov Sells Shares Under 10b5-1 Plan
SEC Form 4 Filing
Fennec Pharmaceuticals CEO Rosty Raykov sold a total of 40,584 common shares on April 3, 2024, under a pre-arranged 10b5-1 trading plan.
Summary
- On April 3, 2024, Rosty Raykov, the CEO of Fennec Pharmaceuticals Inc., sold 14,584 common shares at a price of $10.7782 per share.
- Additionally, Mr. Raykov sold 26,000 common shares at a price of $10.7793 per share on the same day.
- These transactions were executed under a pre-arranged 10b5-1 trading plan established on December 14, 2023.
- Following these sales, Mr. Raykov directly owns 276,054 common shares of Fennec Pharmaceuticals Inc.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing reporting the sale of shares by the CEO. It doesn't inherently convey positive or negative sentiment, as it's a routine disclosure.
Industry Context
Sales by company executives are a normal part of corporate governance. The fact that these sales were executed under a 10b5-1 plan suggests that they were pre-planned and not based on any inside information.
Stakeholder Impact
- The share sales could have a minor impact on shareholders, potentially creating slight downward pressure on the stock price in the short term.
Key Dates
| Date | Description |
|---|---|
| 12/14/2023 | Date of the 10b5-1 plan |
| 04/03/2024 | Date of the share sales |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.